This document is an editorial from the International Journal of Molecular Sciences that discusses recent advancements in cancer treatment. The editorial highlights various innovative approaches, such as nanomedicines, combined therapy, drug repurposing, genomics, and personalized therapy, that target the ...
AstraZeneca Pharma India Ltd has received crucial approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute its cancer treatment medication, Durvalumab.
Over the last five years, new cancer drugs have brought benefits for patients but have increased the cost of treatment, according to the findings of a study published in the British Journal of Cancer . Prior to 2000, 69 cancer drugs, 73% of which were classical cytotoxics, were available...
New drugs called antibody-drug conjugates help patients with cancers that used to be beyond treatment
Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. References: Xu X, et al. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colore...
Meanwhile, patient advocates point out that patients are dying while new drugs await approval. The evidence that MRD predicts survival in newly diagnosed, post-transplant multiple myeloma patients is already good enough, says Jeff Allen, the president and CEO of Friends of Cancer Research, a patien...
Two independent reviewers collected background-, treatment-, disease-, and trial-related variables from FDA labels, clinicaltrials.gov, associated clinical trial publications, and the Global Burden of Disease study for all identified cancer drugs and supporting clinical trials. The first reviewer (D....
Non-small cell lung cancerChemotherapyPhase II drugsDavid S. EttingerLung CancerEttinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113-22.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991;7: 113–122....
This new generation of anticancer drugs – called checkpoint inhibitors – is having such a profound impact that some scientists are pitching it as a turning point in cancer treatment. “Melanoma and lung cancer used to be death sentences, but they’re not any more,” saysGordon Freemanat ...
Since MYC is one of the most frequently altered driver genes involved in cancer formation, it is a potential target for new anti-cancer therapies. Historically, however, MYC has proved difficult to target due to the absence of a suitable crevice for binding potential low molecular weight drugs....